FOSUNPHARMA(SH:600196) Sou Hu Cai Jing·2025-03-26 12:28Core Insights - Fosun Pharma reported a slight decline in revenue for 2024, with total revenue at 41.067 billion yuan, a decrease of 0.8% year-on-year [1][2] - The net profit attributable to shareholders increased by 16.08% to 2.77 billion yuan, while the net profit excluding non-recurring items rose by 15.1% to 2.314 billion yuan [1][2] - The company reduced its R&D personnel by 444, bringing the total to 3,047, which constitutes 7.51% of the total workforce [3][4] Financial Performance - Revenue for 2024: 41.067 billion yuan, down from 41.400 billion yuan in 2023 [2] - Net profit attributable to shareholders: 2.769 billion yuan, up from 2.386 billion yuan in 2023 [2] - Net profit excluding non-recurring items: 2.314 billion yuan, compared to 2.011 billion yuan in 2023 [2] - Cash flow from operating activities increased by 31.13% to 4.477 billion yuan [2] R&D Personnel Changes - R&D personnel count decreased from 3,491 in 2023 to 3,047 in 2024, a reduction of 444 [3][5] - R&D personnel now represent 7.51% of the total workforce, down from 8.65% in the previous year [3][5] - Educational background of R&D staff includes 242 with doctoral degrees and 1,363 with master's degrees [4] Executive Compensation - The total annual salary of the CEO, Wenjie Zhang, is 10.24 million yuan, which is higher than that of the chairman [5][7] - Other executives with salaries exceeding 5 million yuan include Xingli Wang (9.857 million yuan), Rong Yang (6.210 million yuan), and Wang Kexin (5.343 million yuan) [5]